United States Gabapentin Market 2024-2031: Rising Neuropathic Pain, Epilepsy, and Chronic Disorder Treatments Driving Growth | Zydus Pharmaceuticals, Inc., Glenmark Pharmaceuticals Limited, Sun Pharmaceutical Industries Ltd

Global Gabapentin market reached at a Significant CAGR during the forecast period 2024-2031.

The Gabapentin Market is centered around an anticonvulsant drug used to treat epilepsy, neuropathic pain, and restless leg syndrome. Rising prevalence of chronic pain conditions drives demand globally. Generic availability and favorable reimbursement policies boost market accessibility. Research into extended-release and combination formulations enhances clinical outcomes. However, regulatory scrutiny over misuse influences distribution strategies. The market maintains steady growth supported by expanding neurological disorder incidence.

📌 Download Sample Report to Identify Emerging Deals & Opportunities in the Gabapentin Market Landscape:- https://datamintelligence.com/download-sample/gabapentin-market?rk

☛ Gabapentin Market Recent Developments 2025:

United States:

✅ In July 2025, Pfizer expanded its gabapentin production to meet increasing demand for neuropathic pain and seizure management.

✅ In June 2025, Mylan Pharmaceuticals launched an extended-release gabapentin formulation to improve patient compliance.

Japan:

✅ In August 2025, Sumitomo Pharma introduced generic gabapentin formulations optimized for neuropathic pain treatment.

✅ In May 2025, Taisho Pharmaceutical expanded research on combination therapies incorporating gabapentin for chronic pain management.

☛ Gabapentin Market Trends:

Gabapentin is used for neuropathic pain, epilepsy, and anxiety disorders. Growth is driven by rising neurological disorder prevalence and increasing off-label use.

Trends include extended-release formulations and combination therapies. North America and Europe dominate due to high prescription rates, while Asia-Pacific grows with increasing awareness. Regulatory scrutiny and side-effect management are challenges.

☛ Gabapentin Market Competitve Landscape:

Zydus Pharmaceuticals, Inc., Glenmark Pharmaceuticals Limited, Sun Pharmaceutical Industries Ltd., Ascend Laboratories, LLC, Apotex Inc., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma USA, Amneal Pharmaceuticals LLC, Pfizer Inc., and Cipla Inc.

Research Methodology

We follow a hybrid research approach, combining qualitative insights with rigorous quantitative analysis to deliver reliable and comprehensive market intelligence. Our process begins with extensive secondary research, drawing on trusted industry reports, proprietary databases, and credible market sources. This is then reinforced through targeted primary research, including structured surveys and in-depth interviews with industry leaders, subject matter experts, and key market participants.

📌 Request a Customized Market Report - Tailored insights to match your business goals: https://datamintelligence.com/customize/gabapentin-market

☛ Segment Covered in the Gabapentin Market:

By Type: eneric, Branded

By Dosage Form: Tablet, Capsule, Solution

By Application: Neuropathic Pain, Epilepsy, Restless Leg Syndrome, Anxiety, Others

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

☛ This Report Includes:

✔ Comprehensive go-to-market strategies with actionable insights.

✔ Unbiased evaluation of overall market performance.

✔ Deep-dive analysis into development trends, competitive landscape, supply-demand dynamics, YoY growth, benchmarking, vendor mapping, market access, and overall progress.

✔ Tailored regional and country-level reports with detailed localized analysis available on request.

✔ Identification of niche segments and high-growth regions presenting strong opportunities.

✔ Accurate regional forecasts using both top-down and bottom-up approaches.

📌 Get Corporate Access to Live Gabapentin Industry Intelligence Database: https://www.datamintelligence.com/buy-now-page?report=gabapentin-market

☛ Regional Analysis for Gabapentin Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

☛ FAQ's

Q: Which regions are dominating the Gabapentin Market and which are fastest-growing?

A: North America dominating the Gabapentin Market.

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.